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The anti-tumor efficacy of liposomal formulations of cell cycle dependent anticancer drugs is critically dependent on the rates at which the
drugs are released from the liposomes. Previous work on liposomal formulations of vincristine have shown increasing efficacy for
formulations with progressively slower release rates. Recent work has also shown that liposomal formulations of vincristine with higher drug-
to-lipid (D/L) ratios exhibit reduced release rates. In this work, the effects of very high D/L ratios on vincristine release rates are investigated,
and the antitumor efficacy of these formulations characterized in human xenograft tumor models. It is shown that the half-times (T1/2) for
vincristine release from egg sphingomyelin/cholesterol liposomes in vivo can be adjusted from T1/2 = 6.1 h for a formulation with a D/L of
0.025 (wt/wt) to T1/2 = 117 h (extrapolated) for a formulation with a D/L ratio of 0.6 (wt/wt). The increase in drug retention at the higher D/L
ratios appears to be related to the presence of drug precipitates in the liposomes. Variations in the D/L ratio did not affect the circulation
lifetimes of the liposomal vincristine formulations. The relationship between drug release rates and anti-tumor efficacy was evaluated using a
MX-1 human mammary tumor model. It was found that the antitumor activity of the liposomal vincristine formulations increased as D/L ratio
increased from 0.025 to 0.1 (wt/wt) (T1/2 = 6.1–15.6 h respectively) but decreased at higher D/L ratios (D/L = 0.6, wt/wt) (T1/2 = 117 h). Free
vincristine exhibited the lowest activity of all formulations examined. These results demonstrate that varying the D/L ratio provides a powerful
method for regulating drug release and allows the generation of liposomal formulations of vincristine with therapeutically optimized drug
release rates.
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Liposomal formulations of anticancer drugs can result in
increased activity and reduced toxicity compared to the free drug
[1–5]. The benefits of liposomal encapsulation are, however,
dependent on the rates of drug release from the liposomes,
leading to the need to develop formulations that exhibit thera-Abbreviations: SM, Egg sphingomyelin; [3H]-CHE, [3H]-cholesterylhex-
adecyl ether; MLV, multilamellar vesicles; LUV, large unilamellar vesicles;
FBS, fetal bovine serum; D/L ratio, drug-to-lipid ratio
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doi:10.1016/j.bbamem.2006.01.009peutically optimized drug release rates. Such therapeutically
optimized release rates have not been developed for any
liposomal formulation of any drug to date. The major focus of
research efforts has been on developing liposomal formulations
that are small (diameter ∼100 nm) and long circulating in order
to take advantage of the “enhanced penetration and retention”
(EPR) effect [6] leading to preferential accumulation of the
liposomes at tumor sites and infection to sites of infection and
inflammation due to the hyperpermeable nature of the
vasculature in these regions [7]. Within the context of these
formulations, there is a clear need to keep the drug encapsulated
during the time it takes to achieve appreciable tumor
accumulation of the carrier, which implies a half-time for drug
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clear need for the drug to be released on arrival at the tumor site
at rates sufficient to provide enough bio-available drug to inhibit
tumor growth.
Previous work has shown that the efficacy of liposomal
formulations of cell cycle-specific drugs such as vincristine is
particularly sensitive to drug release rates. For example, in
studies employing the L1210 and P388 murine leukemia
models, or the A431 human squamous cell carcinoma model,
formulations of vincristine with progressively slower release
rates converted the drug from being essentially inactive to
one that produced 100% cures [8,9]. This dependence on
release rates is consistent with the fact that prolonged
exposure of cells to cell cycle-specific agents results in
greater cell killing in vitro and enhanced antitumor activity in
vivo [10–15]. Thus, prolonged vincristine release from
liposomes accumulated at the tumor site and the resulting
extended tumor cell exposure would be expected to result in
enhanced antitumor activity. However, formulations with
release rates so slow that efficacy is compromised have not
yet been achieved, preventing identification of truly opti-
mized release rates.
Considerable efforts have been made to develop liposomal
vincristine formulations with improved retention and efficacy
properties. These include increasing acyl chain length and
saturation [16], using sphingomyelin (SM) instead of phospha-
tidylcholine [17], and using lower internal pH environments in
the liposome [18–20]. An SM/Chol liposome formulation [21]
was identified as having the best retention properties achievable
(T1/2 in vivo of ∼24 h) using this technology, and this
formulation has shown enhanced efficacy profiles both in
animal models and in humans [22–26].
In recent work, we have shown that the release rates of
vincristine and other drugs from liposomes are highly sensitive
to the drug-to-lipid (D/L) ratio employed in the formulation
[27]. In the case of vincristine an increase in the D/L ratio from
0.1 to 0.3 (wt/wt) results in an increase in the half-time for drug
release of more than a factor of two. Here, we explore the
possibility that, at higher D/L values achievable through the use
of an ionophore-based drug accumulation technique [28], rates
of drug release can be so slow that a therapeutically optimized
release rate can be identified. In addition, studies to determine
the mechanism whereby increased D/L values lead to improved
retention have also been performed; with particular attention
paid to the possibility that high D/L values lead to precipitation
of the drug in the liposome interior.
2. Materials and methods
2.1. Materials
Egg sphingomyelin (SM) was purchased from Northern Lipids (Vancouver,
BC, Canada) and was used without further purification. Vincristine sulfate was
obtained from Fine Chemicals (Cape Town, South Africa). Cholesterol (Chol)
was obtained from Sigma (St. Louis, MO, USA) and used without further
purification. [3H]-Cholesterylhexadecyl ether (CHE) was obtained from Perkin
Elmer Life Sciences (Boston, MA, USA). [14C]-vincristine sulfate was obtained
from Chemsyn Laboratories (Lenexa, KS, USA). All other chemicals were
obtained from Sigma (St. Louis, MO, USA).2.2. Liposome preparation
Lipids (SM or Chol) and trace amounts of [3H]-CHE were co-dissolved at
appropriate molar ratios in ethanol. Multilamellar vesicle (MLV) suspensions
were generated after the addition of a 300-mM aqueous solution of magnesium
sulfate, yielding a final ethanol concentration of 10% (v/v). Large unilamellar
vesicles (LUVs) were generated by extrusion of MLVs through two stacked
Nuclepore polycarbonate filters with a pore size of 100 nm (10 passes) using an
extrusion device obtained from Northern Lipids (Vancouver, BC, Canada)
[29,30]. A transmembrane ion gradient was established through the removal of
the external 300 mM magnesium sulfate by dialysis against SEH loading buffer
(300 mM sucrose, 3 mM EDTA, 20 mMHEPES, pH 7.4). The mean diameter of
LUVs was determined by dynamic light scattering using a NICOMP 370
particle sizer (Nicomp Particle Sizing Inc., Santa Barbara, CA) and found to be
110 ± 25 nm. Phospholipid concentrations were determined using established
techniques [31] and the specific activity of the liposomes was determined using
a Beckman LS3801 scintillation counter (Fullerton, CA, USA).
2.3. Vincristine encapsulation in liposomes
Vincristine was encapsulated into LUVs using an ionophore-mediated drug
loading procedure, as described previously [28]. Briefly, vincristine sulfate and
trace amounts of [14C]-vincristine sulfate were added to LUVs (5 mm final lipid
concentration) at appropriate drug-to-lipid ratios (wt/wt), and subsequently pre-
incubated at 65 °C prior to the addition of the calcium ionophore A23187. The
LUV/drug/ionophore mixture was then incubated at 65 °C for 90 min to provide
optimal drug loading conditions. Non-encapsulated vincristine was removed
using dialysis against SEH loading buffer [28] prior to quantification of
liposome entrapped drug using dual channel counting on a Beckman LS 3801
scintillation counter. Formulations used for in vivo studies received additional
dialysis into 300 mm sucrose prior to quantification of liposome-entrapped drug.
2.4. In vitro release of vincristine
In vitro drug release assays were performed to make quantitative
comparisons of drug leakage between formulations of varying drug-to-lipid
ratios. Initially, in vitro release assays for liposomal vincristine were conducted
using ammonium chloride to degrade the pH gradient [32]. Drug-loaded vesicles
were diluted with release buffer (2 mM ammonium chloride, 300 mM sucrose,
20 mM HEPES, 3 mM EDTA, pH 7.4) to a lipid concentration of 1.25 mM. The
diluted liposomal drug was then placed into dialysis tubing (12–14 K M.Wt. cut
off) and dialyzed against release buffer at 50 °C. This temperature was chosen to
provide an optimal and convenient in vitro drug leakage rate, generally 20–30%
after 60 min for a drug-to-lipid ratio of 0.05 (wt/wt). Leakage of vincristine from
the loaded LUVs was assayed by the removal of aliquots for spin column
analysis and quantification using dual label liquid scintillation counting [28,33].
Vincristine release from liposomes was also assessed using fetal bovine serum.
Liposomal drug in SEH loading buffer was added to fetal bovine serum (FBS;
Invitrogen, San Diego, CA) to give a final total lipid concentration of 1.25 mm
and a final FBS concentration of 50% (v/v). Samples were incubated at 50 °C.
Vincristine release was quantified over time through the removal of aliquots for
spin column analysis and dual label liquid scintillation counting. The halftimes
for drug release (T1/2) were calculated from exponential best fits to the release
profiles as the time at which the internal drug concentration was half the initial
concentration. Error bars were calculated from the 95% confidence intervals
associated with the exponential best fits.
2.5. Mice
Female, 6- to 8-week-old outbred ICR mice were obtained from Harlan
(Indianapolis, IN) and were used for pharmacokinetic and drug leakage studies.
Female, 6–8 week old, athymic Crl:CD-1®-nuBR mice were obtained from
Charles River Laboratories (Quebec, Canada) and used for the antitumor efficacy
studies. All mice were quarantined for at least 2 weeks prior to use.
Immunocompromised animals were maintained under sterile conditions, with a
controlled temperature (22 ± 1 °C) and humidity (60 ± 10%) environment.
Lighting was maintained on automatic 12 h light/dark cycles. Animal studies
were conducted in compliance with the guidelines established by the Canadian
Council on Animal Care (CCAC).
Fig. 1. Trapping efficiencies for formulations of liposomal vincristine at
increasing initial drug-to-lipid ratios. Vincristine was loaded using the ionophore
method, described in Materials and methods, into SM/Chol liposomes (55/
45 mol%). Data points represent mean loading efficiencies (±standard
deviations) calculated from 3 samples.
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Vincristine loaded LUVs were prepared at various drug-to-lipid (D/L) ratios
and contained 300 mM sucrose as the external buffer. In most instances, drug
and lipid concentrations were adjusted to 0.2 mg/ml vincristine and 4 mg/ml
total lipid, resulting in drug and lipid doses of 2 and 40 mg/kg, respectively, in
mice. Empty SM/Chol liposomes were included in liposomal vincristine
formulations prepared with higher D/L ratios to ensure that mice were injected
with an equivalent total lipid dose. In some instances, formulations with
different D/L ratios were injected into mice at equivalent lipid doses (no empty
liposomes) to determine whether formulations with high drug-to-lipid ratios
exhibited altered pharmacokinetics. Mice were injected via a lateral tail vein
and, at appropriate time points, were anesthetized (ketamine/xylazine) and blood
was collected via cardiac puncture into EDTA Microtainer tubers. Blood was
then centrifuged at 400 × g for 15 min and plasma was collected and de-
colorized for lipid and drug determination by dual label liquid scintillation
counting as described previously [28].
2.7. In vivo efficacy studies
MX-1 human mammary adenocarcinoma was obtained from the Division of
Cancer Treatment and Diagnosis (DCTD) Tumor Repository (Frederick, MD),
maintained by serial passage in vivo and implanted by trocar into the dorsal
flank of nude mice. Experiments were performed between the fourth and tenth
serial passage in nude mice. Treatments were initiated in all models when tumor
volumes were 200–300 mm3 (14 days post tumor implantation). Animals were
dosed according to body weight (10 ml/kg body weight) and received a single
intravenous (i.v.) injection of one of several formulations of liposomal
vincristine. Liposomal vincristine formulations were diluted to achieve a total
lipid dose of 66 mg/kg and a drug dose of 1.5 mg/kg body weight. As with the
pharmacokinetic studies, empty liposomes were included, as appropriate to
ensure mice received equivalent total lipid doses for all drug-to-lipid ratios.
Tumors were measured at least three times per week with calipers and tumor
volume (mm3) was calculated using the formula: (length × width2)/2, where
width was the smaller of the two perpendicular measurements [34]. Tumor
growth delay (T − C); the median difference in time (days) for treated and
control tumors to reach 1000 mm3, was evaluated for each treatment group.
2.8. Cryo-transmission electron microscopy
Cryogenic transmission electron microscopy (cryo-TEM) was performed on
empty and drug-loaded SM/Chol liposomes using a Zeiss EM 902A
Transmission Electron Microscope (LEO Electron Microscopy, Oberkochen,
Germany) operated at 80 kV in the zero loss bright-field mode. Digital images
were recorded under low dose conditions with a BioVision Pro-SM Slow Scan
CCD camera (Proscan GmbH, Scheuring, Germany) and analySIS software
(Soft Imaging System, GmbH, Münster, Germany). In order to visualize
maximum detail, an underfocus of 1–2 μm was used to enhance the image
contrast. Sample preparation was performed at 25 °C and approximately 99%
relative humidity within a climate chamber. As mall drop (ca 2 ml) of sample
was deposited on a copper grid covered with a perforated polymer film coated
with carbon on both sides. Excess liquid was removed by blotting with filter
paper, leaving a thin film of the solution on the grid. Immediately after blotting,
the sample was vitrified by plunging the grid into liquid ethane held at −182 °C.
Samples were maintained below −165 °C and protected against atmospheric
conditions during both transfer to the TEM and examination. Images at
100,000× total magnification were captured for each sample.
3. Results
3.1. Vincristine can be loaded into liposomes to high
drug-to-lipid ratios employing the ionophore loading technique
Previous work [27] has shown that vincristine loaded into
LUVs using an ionophore loading technique exhibits improved
retention at higher D/L values. For example, increasing the D/Lvalue from 0.1 to 0.3 (wt/wt) resulted in an increase in the half-
time for retention by more than a factor of two. Initial work was
therefore devoted to characterizing this effect further and, in
particular, extending the range of D/L ratios that could be
achieved. SM/Chol (55/45 mol) LUVs were prepared contain-
ing 300 mMMgSO4 as described in Materials and methods and
incubated in the presence of increasing amounts of vincristine
corresponding to D/L ratios, if all the drug was accumulated, of
up to 1.5. The LUVs were then dialyzed at room temperature for
2 h to remove untrapped drug and the D/L ratio measured as
described in Materials and methods. As shown in Fig. 1, the
efficiency of the accumulation process in the presence of the
ionophore A23817 decreased at the higher vincristine con-
centrations, however D/L ratios as high as one (wt/wt) were
achieved with approximately 50% trapping efficiency at the
highest external vincristine concentrations employed.
3.2. The half-time of vincristine release from LUVs is linearly
dependent on the drug-to-lipid ratio in vitro and in vivo
The next set of experiments were aimed at characterizing the
release characteristics of SM/Chol LUVs loaded to achieve D/L
ratios of up to 0.6 (wt/wt). Two in vitro assays were employed
that resulted in release rates occurring on experimentally
convenient timescales. The first involved incubation in the
presence of 2 mM NH4Cl at 50 °C, where the presence of the
NH4Cl raises the interior pH of the LUVs, converting more of
the encapsulated drug to the neutral, membrane permeable
form. The second assay involved incubation in the presence of
50% fetal bovine serum at 50 °C. Increased leakage in this case
arises from adsorption of serum proteins to the LUV, thus
increasing the permeability of the lipid bilayer. The high
temperature was employed because incubation at 37 °C did not
result in sufficiently rapid release characteristics. As shown in
Fig. 2, both assays showed dramatic reductions in release rates
as the D/L ratio is increased, corresponding to increases in the
Fig. 2. Vincristine retention in SM/Chol (55/45, mol) liposomes in vitro. Panel
A: retention in 2 mm ammonium chloride at 50 °C; formulations had drug-to-
lipid ratios (wt/wt) of 0.05 (▾), 0.1 (▴), 0.2 (■), 0.35 (●) and 0.64 (♦). Panel B:
retention in 50% FBS at 50 °C; formulations had drug-to-lipid ratios (wt/wt) of
0.05 (▾), 0.1 (▴), 0.2 (■), 0.4 (●) and 0.7 (♦). The lipid concentration in the
release assays was 1.25 mm total lipid. Data points represent mean drug
retention (±standard deviations) calculated from 3 samples and are represen-
tative of at least 3 separate experiments.
Fig. 3. Vincristine retention of SM/Chol (55/45, mol) liposomes in vivo. ICR
mice were injected intravenously with SM/Chol formulations of vincristine
having drug-to-lipid ratios (wt/wt) 0.025 (▾), 0.05 (▴), 0.1 (■) and 0.33 (●). All
mice received lipid doses at 40 mg/kg total lipid and vincristine at 2 mg/kg drug,
with the exception of the 0.025 D/L ratio sample which was dosed at 1 mg/kg
vincristine. Rate constants for release were calculated to be 0.1128 (T1/2=6.1 h),
0.079 (T1/2=8.7 h), 0.0443 (T1/2=15.6 h) and 0.0106 h
−1 (T1/2=65 h) for D/L
ratios of 0.025, 0.05, 0.1 and 0.33, respectively. Data points represent mean
values (±standard deviations) calculated from 3 mice.
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The drug retention properties of liposomal vincristine for-
mulations with different D/L ratios were also evaluated in vivo.
Outbred ICR mice were injected intravenously with liposomal
vincristine formulations with D/L ratios of up to 0.33 at a dose
corresponding to 2 mg/kg vincristine, which is the maximum
tolerated dose of the free drug [8]. Since the total lipid dose can
strongly affect the pharmacokinetic properties of liposomes
[35], empty SM/Chol liposomes were included with drug-
loaded formulations having higher D/L ratios to ensure that
mice received an equivalent lipid dose of 40 mg/kg in all situa-
tions. Blood was collected at appropriate time points and
assayed for total vincristine and total lipid. Note that free vin-
cristine is rapidly removed the circulation with the half-time for
clearance of free vincristine less than 5 min [9] and thus the total
amount of vincristine in the blood overwhelmingly reflects
liposome-encapsulated drug [36]. As shown in Fig. 3, a remark-able increase in the retention properties of the LUVs is observed
as theD/L ratio is increased, corresponding to an increase in T1/2
from ∼6 h for a D/L ratio of 0.025 to more than 60 h for a D/L
ratio of 0.33.
If it is assumed that the efflux of vincristine from LUVs
obeys Fick's law, which states that the efflux rate is
proportional to the area of the LUV membrane and the
concentration gradient of vincristine across the membrane, then
it is straightforward to show that [Di(t)] = [Di(o)]exp (−kt),
where [Di(t)] is the concentration of drug inside the LUV at
time t, [Di(o)] is the interior concentration of drug at time 0 and
k is the rate constant associated with the release process. It
follows that [Di(t)] / [Di(o)] = exp(−kt) and thus that the %
released over time should be independent of the initial interior
drug concentration, which is in direct contradiction to the
results shown in Figs. 2 and 3. In an effort to understand the
mechanism involved, the T1/2 values calculated from the release
data of Fig. 2 (incubation in the presence of ammonium
chloride) and 3 were plotted as a function of initial D/L ratio. As
shown in Fig. 4, a linear relationship is observed, which is
consistent with a large proportion of the encapsulated drug
being in a precipitated (non-soluble) form (see Discussion). A
linear correlation between D/L ratio and the half-time of drug
retention was also observed when drug leakage was induced by
addition of fetal bovine serum.
3.3. Addition of “empty” liposomes allows equivalent
clearance rates to be achieved for LUVs with different D/L
ratios
At low lipid doses, LUVs are increasingly rapidly cleared
from the circulation [35]. Thus, in order for LUV loaded with
drug at very high D/L ratios to exhibit long circulation lifetimes,
Fig. 4. Correlation of drug-to-lipid ratio and vincristine release half-life in
ammonium chloride (Panel A) (R2=0.991) and in female ICR mice (Panel B)
(R2=0.994). Half-lives were calculated as described in Materials and methods,
and were 15, 30, 53, 102 and 161 min for D/L ratios of 0.06, 0.1, 0.2, 0.35 and
0.64 in vitro and 6.1, 8.7, 15.6 and 65 h for D/L ratios of 0.025, 0.05, 0.1 and
0.33 in vivo. Error bars were calculated from the 95% confidence interval
associated with the best fit analysis.
Fig. 5. Plasma lipid recovery (% of injected dose) of SM/Chol (55/45, mol)
liposomes in vivo. ICR mice were injected intravenously with SM/Chol
formulations of vincristine having drug-to-lipid ratios (wt/wt) 0.025 (▾), 0.05
(▴), 0.1 (■), 0.33 (●) and 0.4 (♦). All mice received lipid doses at 40 mg/kg
total lipid and vincristine at 2 mg/kg drug, with the exception of the 0.025 D/L
ratio sample which was dosed at 1 mg/kg vincristine and the 0.4 D/L ratio
sample which was dosed at 20 mg/kg vincristine and 50 mg/kg total lipid. Data
points represent mean values (±standard deviations) calculated from 3 mice.
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lipid dose required for long circulation lifetimes in combination
with reasonable drug dose levels. For example, the maximum
tolerated dose of vincristine is approximately 2 mg/kg in mice. If
this dose was given in LUVs containing vincristine at aD/L ratio
of one (wt/wt), this would correspond to a lipid dose of also
2 mg/kg, which is well below the lipid dose level at which dose-
independent pharmacokinetics are observed for most LUV
compositions [35]. However, as shown in Fig. 5, by adding
empty liposomes to liposomal vincristine formulations with
increasing D/L ratios to achieve constant lipid doses of 40 mg/
kg, the circulation lifetimes following intravenous administra-
tion in vivo achieved are constant, with a half-time for clearance
of approximately 8 h. Further, in order to show directly that high
drug contents do not affect clearance behavior, the clearance
behavior of LUVs with a D/L ratio of 0.4 (wt/wt) with no empty
liposomes, administered at a vincristine dose of 20 mg/kg
(corresponding to a lipid dose of 50 mg/kg), was also examined.The clearance behavior of these systems was no different than
other formulations (Fig. 5).
3.4. Liposomes containing high levels of vincristine show
internal morphology consistent with drug precipitation
Structural and morphological changes in liposomes, attrib-
uted to precipitation of encapsulated drug, have been observed
employing cryo-transmission electron microscopy (cryo-TEM)
when certain drugs, such as doxorubicin, are loaded into lipo-
somes [37]. In addition, previous studies have indicated that
precipitation of encapsulated drug may enhance in vitro and in
vivo drug retention [38]. Our previous cryo-EM studies on
liposomal vincristine formulations [27] have shown that in-
creasing internal electron densities are observed as the D/L ratio
is increased to 0.3, however, no unambiguous evidence for drug
precipitates was observed. Efforts were therefore made to
produce liposomal vincristine formulations with the highest D/L
ratios achievable in order to visualize potential internal struc-
tures. As shown above (Fig. 1), D/L ratios as high as 1 (wt/wt)
can be achieved using the ionophore technique. Cryo-TEM
studies were therefore conducted to include LUVs with these
very high vincristine contents. As shown in Fig. 6, a progressive
increase in intravesicular electron density as the D/L (wt/wt)
ratio is increased from 0 to 1.0 is observed (Fig. 6, panels A–E).
This increase in electron density could represent an amorphous
or gel-like precipitate at the lower vincristine contents.
However, at the D/L ratio of 1.03 (wt/wt), a large proportion
of the liposomes contains electron dense granular structures
within the vesicles (Fig. 4, panel F). These structures, which are
unlike the more linear precipitates observed for drugs such as
doxorubicin and topotecan [38,39], represent the first direct
Fig. 6. Cryo-transmission electron microscopy of SM/Chol (55/45, mol) liposomes containing vincristine at different drug-to-lipid ratios. Liposomes containing
300 mm internal magnesium were loaded with vincristine using the ionophore method as described in Materials and methods. Panels represent empty liposomes (A),
and D/L ratios (wt/wt) of 0.06 (B), 0.27 (C), 0.6 (D) and 1.03 (E). Panel F represents an enlarged section of Panel E and shows granulated structures within the
liposomes at higher D/L ratios. The bar in panel A represents 200 nm and all micrographs (A–E) are shown at the same magnification. Each panel is a representative
image taken from at least 5 images per D/L ratio.
Fig. 7. Therapeutic effects of liposomal vincristine formulations with different
D/L ratios (and correspondingly different drug release rates) in the MX-1 human
mammary xenograft model. MX-1 tumors were implanted in the dorsal flank of
nude mice as described in Materials and methods. Once tumors were
appropriately sized (∼150 mm3), mice were treated with 300 mm sucrose
(⋄), 1.5 mg/kg free vincristine alone (□), or various formulations of liposomal
vincristine (SM/Chol, 55/45, mol) at a dose level of 1.5 mg/kg vincristine and
66 mg/kg total lipid, with D/L ratios (wt/wt) of 0.025 (▾, T1/2=6.1 h), 0.05 (▴,
T1/2=8.7 h), 0.1 (■, T1/2=15.6 h) and 0.6 (●, extrapolated T1/2=117 h). Empty
SM/Chol liposomes were used at the higher D/L ratios to keep the total lipid
dose at 66 mg/kg. All mice began treatment on day 14 (arrow), median tumor
volumes are displayed (n=5).
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loaded into LUVs.
3.5. A therapeutically optimized drug release rate can be
achieved for liposomal vincristine
Early studies on liposomal vincristine demonstrated that the
anti-tumor efficacy in a variety of tumor models was very sen-
sitive to the drug release rate. In particular, the efficacy of
liposomal vincristine in the L1210 [8], P388 [33,40] and A431
[21] tumor models was significantly improved over free drug
and showed further improvement as the rate of release of
vincristine was decreased. Obviously, if the rate of drug release
is sufficiently slow, reduced activity would be expected,
however such slow release rates were not achievable with the
technology then available. The formulations with the slowest
rates of release consisted of SM/Chol (55:45) loaded at a D/L
ratio of 0.1 in response to a pH gradient established by entrapped
phosphate buffer, which demonstrated a T1/2 for drug release of
approximately 24 h in vivo [21]. This formulation is currently in
advanced clinical trial for treatment of non-Hodgkin's lympho-
ma [41].
In order to demonstrate that a therapeutically optimized drug
release rate does exist, at least for one tumor model, the antitumor
efficacy of liposomal vincristine was evaluated in the MX-1 human
breast cancer model employing formulations with a variety of D/L
ratios and corresponding large variations in the rates of drug release.
FormulationswithD/L ratios of 0.025 (T1/2 =6.1 h), 0.05 (T1/2 =8.7h),
0.1 (T1/2=15.6h) and0.6 (T1/2=117h, as extrapolated from the results
of Fig. 4b), were employed with the hope of bracketing the optimum
release rate.Tumors were induced in the flanks of female animals,
allowed to grow for 14 days (200–300 mm3) and then the mice
were treated with a single intravenous dose of liposomal vin-
cristine (1.5 mg/kg) using empty liposomes to maintain a
constant lipid dose as the D/L ratio was increased. All treatment
Fig. 8. Therapeutically optimized rates of drug release for liposomal vincris-
tine in MX-1 human mammary xenograft model are in the range of 0.067 h−1
(T1/2=15.6 h). This figure depicts tumor growth delay (T−C, the time taken for
tumors in the treatment group to reach a tumor volume of 1000 mm3 minus the
time taken for the control group) as calculated from the tumor growth profiles
observed in Fig. 7, as a function of the rate of vincristine release (T1/2
−1 ). The
symbols represent T−C for each of the different D/L ratio (wt/wt) formulations:
0.025 (▾), 0.05 (▴), 0.1 (■) and 0.6 (●). The dashed line represents the tumor
growth delay for a single intravenous dose of vincristine at 1.5 mg/kg. Note that
for the point corresponding to a drug release rate of 0.067 h−1 T−C is much
greater than 60 days as there was no tumor re-growth at this release rate. For
didactic purposes the T−C has been arbitrarily set at 90 days for this release
rate.
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untreated animals, and mice that received the high D/L ratio
formulations, which displayed progressively slower drug release
rates, generally exhibited less weight loss (data not shown). All
treatment groups, including vincristine alone, showed initial tumor
regressions at the vincristine dose used (1.5 mg/kg), followed by
tumor regrowth in most groups. As shown in Fig. 7, in all cases,
liposomal vincristine showed superior efficacy over vincristine
alone, regardless of theD/L ratio. Further, significant differences in
efficacy between liposomal formulations were observed depending
on the D/L ratio used. The tumor growth delay T − C, which is the
time taken for tumors in the treatment group to reach a tumor
volume of 1000 mm3 minus the time taken for the control group, is
a commonly used parameter tomeasure relative efficacy of different
formulations. As noted in Fig. 8, T − C values increased from 21
days at the lowest D/L ratio (0.025, wt/wt, T1/2 = 6.1 h) to greater
than 60 days at a 0.1 D/L ratio (T1/2 = 15.6 h), at which time all
animals were tumor free. Importantly, further increases in the D/L
ratio up to 0.6 (wt/wt) (T1/2 release = 117 h), resulted in a decrease in
activity (T − C = 29 days). At this D/L ratio, drug retention is long
and the reduced activity observed suggests that drug release is
sufficiently slow that antitumor activity is compromised.
4. Discussion
This study demonstrates that the release rates of vincristine
from liposomes can be regulated by varying the drug-to-lipid
ratio and that, at high D/L ratios in SM/Chol liposomes,
therapeutically optimized rates of release can be achieved.
There are four major points of interest. The first concerns theextremely high D/L ratios that are demonstrated here for
vincristine, which are considerably higher than achieved
previously. The second concerns the mechanism whereby
changes in the D/L ratio can modulate drug release rates. The
third concerns the great variations in activity that are observed
for liposomal formulations of vincristine with different release
rates and how this may relate to the drug mechanism of action.
A final point concerns whether optimized release rates
determined in specific cancer models are relevant to liposomal
formulations used clinically.
The results reported here demonstrate that vincristine can be
loaded into LUVs, employing the ionophore loading procedure, to
achieve D/L ratios as high as one, which is close to the maximum
that is theoretically possible (the vincristine levels that could
theoretically be achieved in exchange for 300 mMMg2+ entrapped
in a 100-nm diameter LUVs corresponds to a D/L ratio of ∼1.1).
Such highD/L ratios have not been reported previously for any drug
or drug loading protocol. For example, the highest levels of
doxorubicin reported [42,43] correspond to D/L ratios of
approximately 0.3 (wt/wt), for vincristine to 0.3 (wt/wt) [27], for
topotecan to 0.3 (wt/wt) [38] and vinorelbine to 0.3 (wt/wt) [44].
Aside from the obvious utility of systems with very highD/L ratios
for achieving extremely slow release times in vivo (the T1/2 for a
liposomal vincristine system with a D/L ratio of one can be
extrapolated to be approximately 8 days in vivo), these systems are
of interest because of the extremely high potency of each liposomal
entity. For example, a D/L ratio of one corresponds to
approximately 84,000molecules of vincristine per 100 nmdiameter
liposome (see Appendix A). Although it is difficult to accurately
determine the number of vincristinemolecules required to kill a cell,
an estimate can be achieved from the IC50 values (concentrations of
drug required to inhibit cell growth in vitro by 50%) that have been
reported in the literature. In particular, for exposure times of 24–
48 h, IC50 values in the range of 10 nm have been observed for
L1210 murine leukemia cells [8] and for a variety of human tumor
cell lines [45]. These studies employed approximately 105 cells per
well. Although neither of these studies reported the actual volume
of 10 nm vincristine that was added to the wells, a volume of 200 μl
would be a reasonable assumption. It may then be calculated that
the IC50 corresponds to approximately 10
7 molecules of vincristine
per cell. Thus, even in the unlikely event that all of the vincristine in
the solution partitions into the cells and is required to inhibit cell
growth, this would be supplied by only 120 liposomes with a D/L
ratio of 1. In the more realistic scenario, where the drug partitions
into the cells according to its octanol–water partition coefficient
(log P = 2.14) [46], the concentration in the cells would be
approximately 1.4 μM, corresponding to approximately 440,000
vincristinemolecules per 10μMdiameter cell, requiring delivery of
only five liposomes per cell. Such highly potent liposomes may
well be of utility in targeting applications, particularly when the
number of cell surface receptors that are targeted is limited.
The mechanism whereby higher D/L ratios lead to reduced
release rates is of obvious interest. As indicated under Results, if
drug release is governed by the usual Fick's law relationship,
the efflux rates should be proportional to the total amount of
encapsulated drug and the percent of drug released over time
should be independent of the initial interior drug concentration,
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can, however, be accounted for if the large bulk of the encap-
sulated drug exists in a precipitated form at equilibrium with a
small proportion of the drug in the soluble form. Under these
conditions the efflux rate will be proportional to the concen-
tration of the soluble form of the drug, which will remain
constant until the precipitated form is dissolved. Thus, the half-
time (T1/2) for drug release will be proportional to the amount of
drug in the precipitated form. If the bulk of the drug is in the
precipitated form over the range of D/L ratios examined, the
half-times for drug release from the various formulations will
then be directly proportional to the initial D/L ratio, as observed
experimentally.
The proposal that vincristine precipitates in the liposome
interior is consistent with the results presented here, particularly
the cryo-EM studies on formulations with the highest D/L
ratios, where well defined interior structures became apparent at
D/L ratios of 1. At lower D/L ratios the liposome interior
becomes increasingly electron dense, however precipitated par-
ticulates are difficult to discern. It is likely that the increasing
electron density reflects the presence of precipitated vincristine
in an amorphous form, given the linear dependence of the
release rate on the D/L ratio over the entire range of D/L ratios
examined. The appearance of the precipitate contrasts with that
observed for liposomal formulations of other anti-cancer drugs
such as doxorubicin [47], mitoxantrone [48] and topotecan [38],
where well-defined internalized precipitates are observed at
much lower D/L ratios. In the case of topotecan [49] it was
noted that a formulation with a D/L ratio of 0.2 exhibited
internal precipitates and improved retention compared to
formulations with lower D/L ratios, consistent with the results
presented here for vincristine.
It has long been recognized that the efficacy of liposomal
formulations of vincristine is highly sensitive to the drug release
rate, a point that is reinforced by the results presented here
employing the MX-1 human breast cancer model. Early studies
using the L1210 and P388 murine leukemia models [16,40], and
the A431 human squamous carcinoma model [21] demonstrated
that formulations with slow release rates essentially converted
the drug from being inactive to one that produced 100% cures.
This behavior contrasts with that of other drugs, such as doxo-
rubicin, where release rates have a much smaller effect on
activity in the L1210 model [43] or the orthotopic 4T1 murine
mammary carcinoma model [50]. In the latter study, the maxi-
mum tumor growth delays were less than 50% even though the
doxorubicin halftimes for release were varied over a range of
approximately 7 h to 10 days. It has been proposed [51] that the
reason for this difference concerns the fact that vincristine is a
cell cycle-specific drug [52,53], whereas doxorubicin is not [54].
Extended drug release at tumor sites would be expected to have
the greatest benefit for cell cycle-specific agents, such as
vincristine, where strong relationships between tumor cell
exposure times and enhanced cell killing have been established
[10–15].
The sensitivity of the activity of liposomal formulations of
vincristine to the release rate of the drug naturally leads to the
question of what is the therapeutically optimized rate of drugrelease. As indicated in Fig. 8, the efficacy of formulations with
different payout rates would be expected to exhibit little or no
activity if the drug is released extremely slowly and activity
similar to that observed for the free drug if the drug is released
very quickly after administration. The fact that at rates of release
intermediate between these two extremes enhanced activity
compared to the free drug is observed implies that a thera-
peutically optimized rate of drug release exists. As indicated
under Results, the efficacy of previous formulations of lipo-
somal vincristine improved as the rate of drug release was de-
creased, however rates of drug release that were so slow that
activity was compromised could not be achieved and thus truly
optimized rates of drug release could not be identified. As
demonstrated here, a formulation with a D/L ratio of 0.6 (wt/wt)
with an extrapolated in vivo T1/2 of 117 h exhibits reduced
efficacy compared to a formulation with a D/L ratio of 0.1 (wt/
wt) with a T1/2 of 15.6 h, implying that the optimized rate of drug
release corresponds to a T1/2 intermediate between 16 h and
117 h. It may be concluded that a formulation with a D/L ratio
between 0.1 and 0.6 will exhibit therapeutically optimized
properties in the MX-1 human xenograft tumor model.
The final point of discussion concerns the relation between
optimized rates of release observed in a human xenograft model
and formulations with release rates that are clinically optimal.
Human tumors grow over a period of months to years, whereas
murine and human tumor xenograft models in mice grow over
days, weeks or months. Cell growth rates and tumor doubling
times of the various preclinical models would be expected to
influence the determination of optimal drug release rates. It is
expected that determination of optimal release rates in tumor
models will, however, have utility. For example, it is likely that
similar levels of free drug are required to achieve tumor cell
killing both in xenograft models and in humans. The use of
animal models to determine the slowest release rates compatible
with activity may therefore be of direct relevance to the clinical
situation, provided that similar levels of total (encapsulated)
drug are delivered to the tumor site in both the model and in
humans. Future work will focus on the influence tumor cell
growth rates and repeat dosing schedules on release rates lead-
ing to optimized therapeutic properties.
In summary, the results presented here show that vincristine
can be loaded into liposomes to achieve very high D/L values,
that by varying the D/L values the rates of drug release from the
liposomes can be varied over a wide range, that this behavior is
consistent with drug precipitation in the LUV interior and that
by varying the D/L ratio formulations with therapeutically
optimized rates of drug release can be developed. It is expected
that such procedures will be applicable to the development of
therapeutically optimized liposomal formulations of other cell
cycle-specific drugs.
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It is straightforward to show that the total number of
vincristine molecules in an SM/Cholesterol liposome is given
by the relation
Nv ¼ 8πR
2ðMs=Mv þMc=LrMvÞWr
Asð1þ Ac=LrAsÞ
where: Nv = no. of vincristine molecules per liposome; R =
radius of liposome; Ms = molecular weight of sphingomyelin;
Mv = molecular weight of vincristine;Mc = molecular weight of
cholesterol; Lr = mole ratio of sphingomyelin to cholesterol;
Wr = weight ratio of vincristine to lipid; As = area per molecule
of sphingomyelin; Ac = area per molecule of cholesterol.
Using R = 50 nm, Ms = 703 [55], Mv = 824 [56], Mc = 387
[55], Lr = 55/45, As = 0.6 nm
2 [57], Ac = 0.4 nm
2 [58] then for
Wr = 1 Nv = 83,700.
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